Xeris Biopharma Holdings, Inc. has reported a significant stock sale by its Chief Legal Officer, Beth Hecht. On November 2, 2026, Hecht sold 25,000 shares of the company's common stock at an average price of $10.2331. This transaction is noteworthy as it reflects ongoing strategic moves within the company and raises questions about insider trading.

Following the sale, Hecht retains ownership of 1,086,130 shares. The sale was executed under a Rule 10b5-1 trading plan that Hecht adopted on May 12, 2026. This plan allows for scheduled sales of stock, which can help avoid any appearance of insider trading.

Background

Xeris Biopharma Holdings, Inc. operates in the pharmaceutical preparations sector, classified under SIC code 2834. The company trades on the Nasdaq under the ticker symbol XERS. As a large accelerated filer, Xeris is subject to strict reporting requirements and regulatory scrutiny.

What the Filing Says

The filing indicates that the transaction was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 12, 2026.

Impact

This stock sale may affect investor sentiment towards Xeris Biopharma, as insider transactions can often lead to speculation about the company's future performance. Analysts and investors will likely scrutinize this transaction to assess its implications for corporate governance and insider trading practices.

What's Next

The filing does not say what happens next.